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The effect of lipoprotein apheresis (Direct Adsorption of Lipids, DALI) (LA) on plasma levels of pentraxin 3 (PTX3), an
inflammatory marker that reflects coronary plaque vulnerability, and expression of PTX3 mRNA was evaluated in patients with
hyperLp(a)lipoproteinemia and angiographically defined atherosclerosis/coronary artery disease. Eleven patients, aged 55 ± 9.3
years (mean ± SD), were enrolled in the study. PTX3 soluble protein levels in plasma were unchanged by 2 sessions of LA; however,
a downregulation of mRNA expression for PTX3 was observed, starting with the first session of LA (𝑝 < 0.001). The observed
reduction was progressively increased in the interval between the first and second LA sessions to achieve a maximum decrease by
the end of the second session. A statistically significantly greater treatment-effect correlation was observed in patients undergoing
weekly treatments, compared with those undergoing treatment every 15 days. A progressive reduction in plasma levels of C-reactive
protein was also seen from the first session of LA, with a statistically significant linear correlation for treatment-effect in the change
in plasma levels of this established inflammatorymarker (𝑅2 = 0.99;𝑝 < 0.001). Our findings suggest that LAhas anti-inflammatory
and endothelium protective effects beyond its well-established efficacy in lowering apoB100-containing lipoproteins.
1. Introduction
The development and progression of atherosclerosis involves
the immune response and inflammation. Among the major
markers of inflammation are two proteins of the pentraxin
superfamily: the acute phase proteins C-reactive protein
(CRP) and pentraxin 3 (PTX3). The pentraxins are acute
phase proteins comprising five units in a cyclic pentameric
structure held together by noncovalent bonds. All pentraxins
share a characteristic C-terminal domain (pentraxin domain)
of 200 amino acids that has within it 8 amino acids that are
highly conserved (pentraxin signature) and are structurally
different according to their short and long chain.
Short pentraxins found in humans include the serum
amyloid P component (SAP) and CRP [1]. Among the long
pentraxins, PTX3 or tumor necrosis factor- (TNF-) inducible
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Table 1: Patient demographics and diagnosis and details of lipoprotein apheresis treatment.
Patient
(𝑁 = 11)
Age, years Male (𝑛 = 10)
Female (𝑛 = 1)
Treatment
frequency
Processed volume, mL DALI configuration Diagnosis CAD
1 47 Male Weekly 10000 1250 HyperLp(a) AWA
2 62 Male Weekly 10000 1250 HyperLp(a) Yes
3 52 Male Biweekly 10000 1250 HyperLp(a) Yes
4 43 Male Biweekly 10000 1250 HyperLp(a) Yes
5 49 Male Biweekly 10000 1000 HyperLp(a) Yes
6 52 Female Biweekly 10000 1250 HyperLp(a) Yes
7 50 Male Weekly 10000 1250 HyperLp(a) Yes
8 73 Male Biweekly 10000 1000 HyperLp(a) Yes
9 51 Male Weekly 10000 1250 HyperLp(a) Yes
10 63 Male Weekly 10000 1250 HyperLp(a) Yes
11 66 Male Weekly 10000 1250 HyperLp(a) Yes
DALI, Direct Adsorption of Lipids; HyperLp(a), hyperLp(a)lipoproteinemia; CAD, coronary artery disease; AWA, arterial wall atherosclerosis assessed by
angiography but no CAD.
gene 14 protein (TGS-14) was the first to be described at the
beginning of the 1990s, when a new domain was identified as
an interleukin-1 (IL-1) inducible gene in endothelial cells and
a TNF-inducible gene in fibroblasts [2, 3]. PTX3 is comprised
of a C-terminus of 203 amino acids (the domain that is
shared with all pentraxins) and a characteristic N-terminus
of 178 amino acids that makes it a long pentraxin. The role
of PTX3 in inflammatory processes has been confirmed by
in vitro studies on cultures of smooth muscle cells from
healthy human arteries incubated with modified atherogenic
lipoproteins [4]. In vivo studies have found a relationship
between the cells of carotid atherosclerotic plaques and
myocytes of patients with acute myocardial infarction with
high levels of PTX3 [5–7]. In contrast to CRP, PTX3 is
expressed at very low levels in the liver and is not expressed
constitutively by the central nervous system if not induced by
inflammatory stimuli. The different sites of tissue expression
reflect the different, heterogeneous roles. Levels of PTX3
are elevated in patients with cardiovascular disease (CVD)
and high values in the general population are considered
to be predictive of CVD, especially in patients with arterial
hypertension and with dyslipidemia. Recent studies suggest
that PTX3 may represent a novel effective marker of car-
diovascular risk [6–8]. Lipoprotein apheresis (LA) with the
DALI (Direct Adsorption of Lipids) system is a relatively
new technique that offers greater cardiovascular protection
through the selective removal of low-density lipoprotein,
very low-density lipoprotein, lipoprotein(a) (Lp(a)), and
inflammatory cytokines directly from whole blood [9]. With
its filtering action, extracorporeal LA plays an important
role in reducing the progression of coronary artery disease
(CAD) in subjects with familial hypercholesterolemia (FH)
and hyperLp(a)lipoproteinemia (HyperLp(a)) [10, 11]. Cur-
rently there is no reported evidence of the effects of LA
on plasma levels of soluble PTX3 and on PTX3 messenger
ribonucleic acid (mRNA) expression. The aim of the current
study was to evaluate the effects of LA on plasma levels
and mRNA expression of PTX3, throughout two consecutive
(weekly or biweekly) treatment sessions of LA, in patients
with genetically determined dyslipidemia (HyperLp(a)) and
associated CAD, assessed by aortocoronary catheterization.
2. Materials and Methods
2.1. Patients. Eleven patients (10 males and 1 female),
aged 55 ± 9.3 years (mean ± standard deviation [SD]),
were enrolled in the study. All patients were affected by
HyperLp(a). Ten patients had documented CAD, and 1 had
nonstenotic atherosclerotic wall abnormalities assessed by
aortocoronary catheterization (Table 1). All patients were
treated with LA. The frequency of treatment was weekly in
6 patients and biweekly (every 15 days) in 5 patients.
2.2. Ethics. Written informed consent was obtained from all
patients, according to the recommendations of the Declara-
tion of Helsinki, guiding physicians in biomedical research
involving human subjects (adopted by the 18th World Med-
ical Association General Assembly, Helsinki, Finland, June
1964, and amended by the 29th World Medical Assembly,
Tokyo, Japan, October 1975, the 35th World Medical Assem-
bly, Venice, Italy, October 1983, and the 41st World Medical
Assembly, Hong Kong, September 1989).
2.3. DALI Procedure. TheDALI system is based on the bind-
ing of positively charged apolipoprotein B100 to negatively
charged polyacrylic acid covalently bound to polymethacry-
lamide. In the present study, DALI apheresis procedures
were performed weekly, with all patients subjected to the
same standardized protocol (adsorber volume 500mL and/or
750mL gel; flow rate Qb 60mL/min). Anticoagulation was
achieved using an initial bolus dose of heparin 20 IU/kg, fol-
lowed by infused citric acid 1mL/20–40mL blood. Vascular
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access was via the antecubital veins, and the mean volume
processed per session was ∼10000mL.
2.4. Laboratory Activities
2.4.1. Sample Collection. Four samples from each of the 11
patients were collected and stored. The 4 samples for each
patient correspond to the following: blood collected before
first apheresis treatment (considered as baseline), PRE1;
blood collected after first apheresis treatment, POST1; blood
collected before second apheresis treatment, PRE2; blood
collected after second apheresis treatment, POST2.
Two naı¨ve samples (one from a nonsick patient and one
from a sick patient) were collected and processed under
the same procedure, for downstream treatment and analy-
sis procedures adjustments and validation. After collection
was completed, the samples were shipped under dry ice
to LabOmics S.A. (Nivelles, Belgium) for proteomics and
transcriptomics analysis.
2.4.2. RT-qPCR Analysis
(A) RNA Extraction. A total of 42 RNA falcon tubes were
shipped to LabOmics including two tubes ABN and NORM
for evaluation purpose.We used TRIzol extraction procedure
followed by cleanup method using the QIAGEN RNeasy
Mini Kit (http://www.qiagen.com/). The RNA was eluted
in 50𝜇L water (RNAse free). RNA concentrations and the
ratio of OD at 260 to 280 nm (A260/280) were measured by
NanoDrop 1000 Spectrophotometer (Thermo Scientific) and
the RNA quality was controlled by Agilent 2100 Bioanalyzer
microfluidic electrophoresis chips. Each RNA sample was
stored at −80∘C.
(B) cDNA Synthesis. RevertAid H Minus First-Strand cDNA
Synthesis Kit (Thermo Scientific) was used to retrotran-
scribe 250 ng of RNA into cDNA. The kit is supplied
with both oligo(dT)18 and random hexamer primers. The
oligo(dT)18 primer anneals selectively to the poly(A) tail
of mRNA. Random hexamer primers do not require the
presence of poly(A). We evaluated the performance of use
of the oligo(dT)18 primers over random hexamer primers.
Reverse transcription of mRNA extracted from 4 patients
was investigated and quantitative real-time polymerase chain
reaction (qPCR) analyses were performed in triplicate using
GAPDH primers in the presence of oligo(dT) and random
hexamers.The yield of cDNAwas investigated and showed no
major difference between random hexamer and oligo(dT)18
primers. This result was confirmed by evaluating the cDNA
synthesis efficiency using qPCR.
(C) qPCRReactions.TheSYBRGreen PCRMasterMix is sup-
plied in a 2x concentration (Life Technologies PN 4309155).
The mix is optimized for SYBR Green reactions and contains
SYBRGreen I Dye, AmpliTaqGoldDNAPolymerase, dNTPs
with dUTP, Passive Reference, and optimized buffer compo-
nents. Real-time PCR was conducted using an ABI 7900HT
SequenceDetection System (Applied Biosystems, Foster City,
California, USA) and quantification was accomplished with
the accompanying software package software version SDS
2.4. The PCR reaction was carried out in 25 𝜇L volumes
and performed in MicroAmp Optical 96-well Reaction Plate
Life Technologies (PN N801-0560) and MicroAmp Optical
Adhesive Film Kit Life Technologies (PN 4313663). All genes
for each sample were assayed in triplicate in the presence of
2 𝜇L of 40-fold diluted first-strand cDNA synthesis reaction
mixture and 20 picomoles of primers. Polymerase activation
at 95∘C for 10min was followed by 40 cycles of 15 s at 95∘C,
30 s at 60∘C, and 30 s at 60∘C.The dissociation curve analysis,
which evaluates eachPCRproduct to be amplified from single
cDNA, was carried out in accordance with themanufacturer’s
protocol. Expression levels were reported as cycle threshold
(Ct) values. Because it was envisioned that ACT1 would
serve as a single-gene normalization control, this gene was
included on each plate. Raw qPCR expression measures
were quantified using Applied Biosystems SDS software and
reported as Ct values. The Ct value represents the number of
cycles or rounds of amplification required for the fluorescence
of a gene or primer pair to surpass an arbitrary threshold.
The magnitude of the Ct value is inversely proportional to
the expression level so that a gene expressed at a high level
will have a low Ct value and vice versa. Triplicate Ct values
were combined by averaging and standard deviation was
calculated. Data normalization was carried out against ACT1
gene an endogenous unregulated reference gene transcript.
The SYBR Green assay was capable of detecting ≥0.01 pg
of PTX3mRNA≥0.1 ng of total RNAwith high specificity and
reproducibility (coefficient of variation for delta Ct <0.9%).
2.4.3. Proteomics: Enzyme-Linked Immunosorbent Assay
(ELISA). The ELISA was performed using a commercial
ELISA kit purchased from Cusabio (http://www.cusabio
.com/) and according to manufacturer’s instructions. PTX3
detection range was 0.156 ng/mL–10 ng/mL and limit of
sensitivity 0.039 ng/mL. The PTX3 ELISA showed no signif-
icant cross-reactivity or interference between human PTX3
and analogues. Measurements of clinical samples were done
in triplicate, and immunoassay values were close to the lower
limit of detection; therefore the <8% intra-assay and <10%
interassay variation had no impact on the reproducibility of
the results.
2.4.4. High-Sensitivity C-Reactive Protein (hsCRP) Analysis.
CRP levels in the study samples were analyzed at the
Altamedica SpA Laboratory, Rome, Italy, by nephelometry
using the Siemens N Cardio Phase hsCRP, 150 tests (Siemens
Healthcare, Milan, Italy) and according to the manufacturer’s
instructions.
2.4.5. Statistical Analysis. All values were expressed as mean
and standard deviation. The comparison of averages was
performed using the Pearson test for correlation between
paired values. Missing data and values out of range were
excluded from the analysis. The values were significant for
𝑝 ≤ 0.001, and the changes were expressed by Δ%. The
𝑅 coefficient of linear correlation applied to the dose-effect
analysis was significant for 𝑅-squared >0.8. All the results
were validated with the statistical program SPSS (v 20.0).
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Figure 1: Effect of LA treatment on PTX3 mRNA expression (a), change in expression (b), and change in expression by LA schedule (c). LA,
lipoprotein apheresis; PTX3, pentraxin 3; QW, once weekly; Q2W, biweekly; PRE1, blood sample collected before first LA session; POST1,
blood sample collected after first LA session; PRE2, blood sample collected before second LA session; POST2, blood sample collected after
second LA session.
3. Results
A statistically significant downregulation of PTX3 mRNA
expression was observed in all 11 patients (𝑝 < 0.001), as
shown in Figure 1(a). The observed reduction started with
the first LA session (from 12.4 ± 1.3 ng/𝜇L PRE1 to 10.8 ±
0.7 ng/𝜇L POST1) and was progressively enhanced during
the interval between the first and second LA sessions (to
9.6 ± 0.8 ng/𝜇L at PRE2), probably due to modulation of
the signal, and a maximum decrease was achieved after the
second LA session (to 9.0 ± 0.8 ng/𝜇L POST2). A statistically
significant treatment-effect linear correlation with 𝑅2 of 0.97
(minimum −13%, maximum −27%) was observed for change
in PTX3 mRNA expression, with progressive reduction as
shown in Figure 1(b). The observed reduction in PTX3
mRNA expression was statistically significantly greater in
patients undergoing weekly LA treatment sessions (𝑅2 =
0.99; minimum −12%, maximum −30%) than in patients
undergoing treatment biweekly (𝑅2 = 0.93; minimum −13%,
maximum 25%). The effect of LA treatment schedule on
change in PTX3 mRNA expression is shown in Figure 1(c).
Plasma levels of soluble PTX3 peptide oscillated over the
course of the two LA sessions. After a slight increase after
the first LA session, from 0.08 ng/mL PRE1 to 0.1 ng/mL
POST1, plasma soluble PTX3 levels (PTX peptide expression,
assessed by ELISA) fell to 0.008 ng/mL PRE2 but climbed
again after the second LA session (to 0.112 ng/mL POST2),
as shown in Figure 2(a). Linear regression analysis revealed
no statistically significant treatment-effect for LA on plasma
soluble PTX3 levels (Figures 2(b) and 2(c)).
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Figure 2: Effect of LA treatment on PTX3 peptide expression (ELISA) (a) and change in expression in all patients (b) and by LA schedule (c)
in patients with HyperLp(a) (𝑛 = 11). LA, lipoprotein apheresis; PTX3, pentraxin; ELISA, enzyme-linked immunosorbent assay; HyperLp(a),
hyperLp(a)lipoproteinemia; POST1, blood sample collected after first LA session; PRE2, blood sample collected before second LA session;
POST2, blood sample collected after second LA session.
C-reactive protein (CRP) levels were also progressively
reduced, starting from the first LA session (from 0.33 ±
0.10mg/dL PRE1 to 0.21 ± 0.08mg/dL POST1, 0.13 ±
0.06mg/dL PRE2, and 0.07 ± 0.04mg/dL POST2), and a
statistically significant linear correlation for treatment-effect
was observed for the change in plasma CRP levels (𝑅2 = 0.99;
minimum −35%, maximum −79%), as shown in Figure 3.
4. Discussion
We studied the effects of a sustained reduction of apoB100-
containing lipoproteins, achieved via LA with the DALI
system, on the expression of mRNA which codifies PTX3
synthesis and on plasma levels of soluble PTX3 protein and
CRP, in patients diagnosed with HyperLp(a) and AWA/CAD.
The increase in plasma levels of soluble PTX3 observed at the
first treatment, present in all patients in this study, including
those treated every 7 days or every 15 days, might be due
to an initial proinflammatory effect of the treatment. It has
previously been noted that hemodialysis increases plasma
levels of PTX3. A potential relationship between PTX3 and
various cytokines removed during extracorporeal treatment
might exist [12–15]. Moreover, evidence from literature has
suggested a link between PTX3 and atherosclerosis. PTX3
is able to interfere with plaque stability due to its link to
fibroblast growth factor 2. In fact, fibroblast growth factor
2 plays a key role in the induction, proliferation, migration,
and survival of vascular smooth muscle cells and in the
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Figure 3: Effect of LA treatment on CRP expression (a), change in expression (b). ∗PRE1 versus POST1 two-tailed 𝑝 value of 0.0039
(considered to be very statistically significant). ∗∗PRE1 versus PRE2 two-tailed 𝑝 value <0.0001 (considered to be extremely statistically
significant). ∗∗∗PRE2 versus POST2 two-tailed𝑝 value<0.0001 (considered to be extremely statistically significant). LA, lipoprotein apheresis;
PTX3, pentraxin 3; QW, once weekly; Q2W, biweekly; PRE1, blood sample collected before first LA session; POST1, blood sample collected
after first LA session; PRE2, blood sample collected before second LA session; POST2, blood sample collected after second LA session.
induction and excessive proliferation of smooth muscle cells
in plaques. In addition foam cells are able to stimulate the
expression of PTX3 in atherosclerotic plaques generating
acute inflammation [16, 17]. Evidence also exists that PTX3
is implicated in the atherosclerotic process by means of other
several mechanisms, including interaction with modified
lipoproteins (oxidized low-density lipoprotein), formation of
foam cells, and the activation of the fall in complement. In
2002, Rolph et al. highlighted the presence of PTX3 during
a carotid thromboendarterectomy that was not present in
healthy mammary arteries and thus assumed that PTX3 is
involved in the proatherogenic inflammatory process [5].
PTX3 levels are elevated in patients with CVD [6, 16],
and elevated levels in the general population are consid-
ered predictors of CVD, especially in patients with arterial
hypertension affected by dyslipidemia [18, 19]. Zanetti et al.
observed a direct correlation between hypertriglyceridemia
and plasma PTX3 concentrations and an inverse correlation
between HDL-cholesterol and PTX3 [19]. In 2000 it was
reported that PTX3 increases during acute inflammation
in patients suffering from acute myocardial infarction [6],
and for this reason PTX3 is considered to be a new bio-
chemical marker in acute myocardial infarction, along with
troponin and creatine kinase [20]. Moreover, a study by
Ryu and colleagues evaluated 376 patients who had ischemic
stroke between September 2004 and September 2006. During
follow-up, 19.4% of the patients died and these patients had
the highest median PTX3 levels [21]. According to Ryu’s
study and other more recent studies, elevated PTX3 levels
are independently associated with an increased mortality
rate after ischemic ictus. This can mean that PTX3 can be
used as a significant prognostic biomarker for patients with
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ischemic ictus [16, 21]. In addition, several different clinical
studies have shown that PTX3 was associated with renal
dysfunction and also, as has been noted, that it represents
an important risk factor for predicting cardiovascular events
[22, 23]. PTX3 is notably elevated in patients with terminal
chronic kidney disease and the relationship between PTX3
and cardiovascular morbidity suggests a possible connection
between PTX3 and arteriosclerosis and CVD in patients
undergoing hemodialysis therapy [12].
In our study, PTX3 mRNA expression was elevated but
soluble plasma protein levels were reduced by the apheresis
sessions but rebounded after session.This suggests a different
impact of DALI-LA on mRNA encoding PTX3 and the
product of gene signaling action at cellular level. Other
authors obtained a reduction of PTX3 with the HELP-LA
system [24], which has a mechanism of action different to
that of DALI-LA (i.e., precipitation induced by high dose of
heparin for HELP versus filtration on gel of polyacrylate for
DALI).
The apparent clearance of CRP by DALI in the absence of
PTX3 clearance is worth noting.The two proteins have differ-
entmolecularweight despite similar structural conformation.
hsCRP is a member of the small pentraxins family with a
molecular weight of 25,106Da versus 40,165Da for PTX3.
The MW of LDL is much smaller at 514 kD. The pore size of
the polyacrylate gel used for DALI might play a role in this
effect, as could inflammatory effects caused by leachates from
filters, tubing, and so forth. Certainly the picture at present is
confusing, but the potential impacts on inflammatory process
in the atherosclerotic plaque are intriguing.
C-reactive protein is an acute phase protein that appears
in circulation in response to inflammatory cytokines, such
as interleukin-6, and serves as a biomarker for systemic
inflammation [25]. Measurement of CRP is useful for the
detection and evaluation of infection, tissue injury, inflam-
matory disorders, and associated diseases, and it has been
shown that CRP levels are of prognostic value in patients
with myocardial infarction and unstable angina [26, 27].
High-sensitivity CRP (hsCRP) measurements are recognized
as a strong independent risk marker for the identification
of individuals at risk for future cardiovascular disease [28].
Whenused in conjunctionwith traditional clinical laboratory
evaluation of acute coronary syndromes, measurements of
hsCRP may be useful as an independent marker of prognosis
for recurrent events in patients with stable coronary disease
or acute coronary syndromes. In our study, we observed
a progressive reduction in CRP levels from the first LA
session and a statistically significant treatment-effect linear
correlation for the change in plasma CRP levels.
In this study, LA (DALI system) showed essentially no
effect on soluble PTX3 levels in plasma. However, impor-
tantly, it was associated with an intense downregulation of
expression of PTX3 mRNA, which codifies PTX3 synthesis,
suggesting a significant change/modulation at a posttran-
scriptional rather than posttranslational level that has not
been previously reported in patients with severe genetically
defined dyslipidemia and associatedCAD.This is particularly
evident because downregulation of PTX3 mRNA expression
was not only linearly correlated with treatment (LA proce-
dure), but also intensified if treatment was weekly, rather than
biweekly.This may suggest that the observed downregulation
ismore intensewhen LA ismore frequently applied.Thus, the
conclusion of this study is that LA directly affects expression
of mRNA codifying for PTX3, probably (but not definitely)
by reducing apoB100-containing lipoproteins. In the light of
the role of PTX3 as a proinflammatory and proatherogenic
marker, it is possible that the application of sustained lipid-
lowering treatment may induce antiatherogenic and (prob-
ably) anti-inflammatory effects that are linked not only to a
reduction of apoB100-containing lipoproteins, but also to the
direct removal of soluble PTX3 protein in plasma exerting a
protective endothelial effect. In clinical practice, this might
be achieved by LA treatment and also possibly by the most
effective available cholesterol-lowering drugs (HMGCoA-
reductase inhibitors/statins). The effects of the latest genera-
tion of lipid-lowering drugs, including proprotein convertase
subtilisin/kexin type 9 inhibitors, cholesteryl ester transfer
protein inhibitors, microsomal triglyceride transfer protein
inhibitors, and apolipoprotein B synthesis inhibitors, should
also be investigated. One last issue for consideration is
that in the light of these findings, and from the evidence
available from both short- and long-term studies, whether
the inhibition of PTX3 achieved by sustained therapeutic
lipid-lowering is transitory or stable should be investigated
and confirmed. Thus, additional follow-up of patients with
genetically determined dyslipidemia and CAD is required,
with well-planned, continuous, long-term treatment to fur-
ther investigate the therapeutic potential of lowering PTX3
directly or through gene-silencing treatments. In particular, a
longitudinal study could offer further insights into cardiovas-
cular hard endpoints, including acute myocardial infarction,
stroke, and need for revascularization interventions.
In conclusion, LA via the DALI method reduced the
expression of PTX3 at the level of mRNA, and this may
contribute to the apparent anti-inflammatory effects of the
procedure.
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